insurance companies that cover glp-1 drugs coverage just changed for as many as 56 million Americans when it comes to the popular medications used to promote weight loss. Story🔗below Medicaid Coverage of and Spending

Medical teams apply this treatment during the first 2448 hours after an ischemic stroke to improve recovery

GLP-1 drug penetration below 4% of eligible patients Top GLP-1 market: United States with 62.8% of global GLP-1 weight loss drug revenue Cardiovascular approval catalyst: Wegovy approved for MACE risk reduction following SELECT trial demonstrating 20% reduction in major adverse cardiovascular events Fastest-growing indication: Obstructive sleep apnea at 41.2% CAGR following Zepbound FDA approval November 2025 Market Overview: Why GLP-1 Weight Loss Drug Market Growth Is Accelerating The GLP-1 Weight Loss Drug Market is at an unprecedented commercial inflection point defined by three simultaneous demand accelerators

Available at: Esteves SC, Miyaoka R, Agarwal A

doi: 10.24171/j.phrp.2023.0261 83 SeighaliNAbdollahiAShafieeAAminiMJTeymouri AtharMMSafariOet al